Welcome to our dedicated page for Merus N.V. Common Shares news (Ticker: MRUS), a resource for investors and traders seeking the latest updates and insights on Merus N.V. Common Shares stock.
Merus N.V. (Nasdaq: MRUS) is a clinical-stage immuno-oncology company focused on creating innovative therapies to treat and potentially cure cancer. At the heart of Merus' approach is its proprietary Biclonics® and Triclonics® technology platforms, which generate full-length human bispecific and trispecific antibodies. These advanced therapeutics are designed to engage the immune system to kill tumor cells and inhibit tumor cell growth pathways simultaneously.
Core Business
Merus' core business revolves around the discovery and development of bispecific antibody therapeutics. Their flagship technology, Biclonics®, can attack tumors in multiple ways, making them highly effective against various cancer types. The company’s portfolio includes several promising candidates, such as MCLA-128, which targets HER2 and HER3 receptors in gastric and breast cancers; MCLA-117, targeting AML; MCLA-158 (petosemtamab), focused on head and neck squamous cell carcinoma; and MCLA-145, developed for solid tumors.
Latest Achievements and News
As of May 2024, Merus has received the FDA's Breakthrough Therapy Designation (BTD) for petosemtamab in treating patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) that has progressed after treatment with platinum-based chemotherapy and PD-1/PD-L1 antibodies. This significant milestone is based on the promising data from the ongoing phase 1/2 trial of petosemtamab as a monotherapy, showing substantial improvement in clinically significant endpoints. Furthermore, Merus has announced plans to initiate a phase 3 trial in mid-2024 to evaluate the combination of petosemtamab and pembrolizumab in previously untreated patients.
Additionally, Merus revealed the acceptance of abstracts for MCLA-145 and MCLA-129 at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. These presentations highlighted the clinical activity of MCLA-145 in advanced solid tumors and the efficacy of MCLA-129 in non-small cell lung cancer (NSCLC).
Financial Condition and Partnerships
Merus has a solid financial foundation, bolstered by strategic partnerships and collaborations. Notably, Merus collaborates with Betta Pharmaceuticals to develop MCLA-129 in China while retaining global rights outside China. The company’s financial strategy includes advancing its clinical development programs and supporting preclinical research and technology development through successful capital raises.
About Merus N.V.
Merus N.V. is dedicated to the development of multispecific antibody therapeutics, referred to as Multiclonics®. These therapeutics have been observed in preclinical and clinical studies to exhibit the same features as conventional human monoclonal antibodies, including long half-life and low immunogenicity. For more information, visit Merus’ official website, Twitter, and LinkedIn.
Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company, announced that its CEO, Bill Lundberg, will participate in a fireside chat at the Jefferies Virtual Healthcare Conference on June 2 at 9:00 a.m. ET. The session will be accessible via a live webcast on the company's Investors page, with an archived version available afterward. Merus focuses on developing innovative multispecific antibodies, particularly its Biclonics® and Triclonics® products, which aim to advance cancer treatment.
Merus N.V. (MRUS) announced interim results from its phase 1/2 eNRGy trial investigating zenocutuzumab (Zeno) in patients with NRG1+ cancers. As of January 12, 2021, 51 patients were treated, with 33 evaluable for response, showing 27% overall response rate (ORR) and 40% ORR in pancreatic cancer. The safety profile remains favorable, with most adverse events mild or moderate. An oral presentation of updated interim analysis is set for ASCO on June 4, and an investor call is planned for June 6 to discuss results and provide program updates.
Merus N.V. (Nasdaq: MRUS) announced new collaborations in Israel, Italy, and Spain to enhance molecular screening for patients with cancers linked to neuregulin 1 (NRG1) fusions and promote the eNRGy clinical trial for its bispecific antibody, zenocutuzumab (Zeno). Progenetics, AISP, and Universidad de Navarra will educate patients and oncologists about these screenings. This initiative aims to improve patient treatment options and potentially recruit more patients for the eNRGy trial, which evaluates Zeno's safety and efficacy in treating NRG1+ cancers.
Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company, announced that CEO Bill Lundberg will participate in a fireside chat at the 2021 RBC Capital Markets Global Healthcare Conference on May 18 at 8:00 a.m. ET. The presentation will be available via a live webcast on the company's Investors page, with an archived version accessible for a limited time afterward.
Merus specializes in developing innovative multispecific antibodies, known as Biclonics® and Triclonics®, aiming to provide advanced therapeutic options in cancer treatment.
Merus N.V. (Nasdaq: MRUS) announced its Q1 2021 financial results, showing a total revenue of $8.35 million, a significant increase from $6.30 million in Q1 2020. The operating loss was $21.79 million, up from $19.57 million year-over-year. Cash and equivalents rose to $374.4 million, bolstered by a follow-on offering and a $60 million collaboration with Lilly. Key highlights include the upcoming ASCO presentation on zenocutuzumab and the advancement of its clinical pipeline with MCLA-145 and MCLA-129 trials. Additionally, Cecile Geuijen was promoted to Chief Scientific Officer.
Merus N.V. (Nasdaq: MRUS) has commenced a phase 1/2 clinical trial for MCLA-129, a bispecific antibody targeting advanced non-small cell lung cancer (NSCLC) and other solid tumors. This trial aims to evaluate safety, tolerability, and clinical activity, focusing on determining the maximum tolerated dose. MCLA-129, developed in collaboration with Betta Pharmaceuticals, has shown promise in preclinical studies for treating EGFR-resistant NSCLC. This strategic initiative marks a significant advancement in Merus' oncology portfolio, aimed at addressing treatment resistance.
Merus N.V. (Nasdaq: MRUS) announced its selection for an oral presentation at the ASCO Annual Meeting from June 4-8, 2021. The presentation will focus on interim clinical data for zenocutuzumab (Zeno), a bispecific antibody targeting NRG1 fusion positive cancers. Currently, patients are being recruited for the phase 1/2 eNRGy trial assessing Zeno's safety and anti-tumor efficacy. The session will be led by Dr. Alison Schram from Memorial Sloan Kettering Cancer Center and will provide updated analyses on this promising candidate.
Merus N.V. (Nasdaq: MRUS) reported its financial results for Q4 and FY 2020, highlighting advancements in its clinical programs. The clinical update for zenocutuzumab is expected in 2Q 2021, focusing on NRG1 fusion cancers, with over 30 patients involved. Collaboration with Loxo Oncology has resulted in $60 million of upfront payments and equity investment. The company aims to extend its financial runway to at least 2H 2024, supported by cash reserves of $207.8 million. R&D expenses increased by $14.4 million, primarily due to escalating costs for zenocutuzumab.
Merus N.V. (Nasdaq: MRUS) has announced its participation in the AACR 2021 Annual Meeting, presenting preclinical data on its innovative multispecific antibodies, zenocutuzumab and MCLA-129. These presentations, scheduled for April 10-15 and May 17-21, 2021, will focus on the effectiveness of zenocutuzumab against tumors driven by NRG1 gene fusions and MCLA-129's role in impairing NSCLC tumor growth. The company aims to showcase the potential of its Biclonics® technology in cancer therapies.
Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company, announced that CEO Bill Lundberg, M.D., will participate in a fireside chat at the 33rd Annual Roth Conference on March 15, 2021, at 2:00 p.m. ET. The event will be accessible via a live webcast on the Company’s Investors page, with an archived version available for a limited time afterward.
Merus is known for developing innovative, full-length multispecific antibodies, branded as Biclonics® and Triclonics®, which have shown promising features in clinical studies.
FAQ
What is the current stock price of Merus N.V. Common Shares (MRUS)?
What is the market cap of Merus N.V. Common Shares (MRUS)?
What is the core business of Merus N.V.?
What are some of Merus' key product candidates?
What significant recent achievement has Merus reported?
What are Biclonics®?
What is the status of MCLA-145 and MCLA-129?
What are Multiclonics®?
Who are Merus' key partners?
What are the financial strategies of Merus?
What is the purpose of the latest capital raise by Merus?
Where can I find more information about Merus N.V.?
